Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12994394 | 0.92 | HTR2A (0.35) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL12907045 | 0.92 | CNR2 (0.35) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL13586463 | 0.89 | CNR2 (0.37) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL12822882 | 0.87 | HTR2A (0.36) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL13586295 | 0.86 | FPR2 (0.37) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL13586562 | 0.85 | FPR2 (0.34) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL12907043 | 0.84 | FPR2 (0.34) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL10303237 | 0.83 | HTR2A (0.35) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL12907753 | 0.83 | HTR2C (0.35) | CNR2HTR2AHTR2CHTR2BSCN9A | |
| SCHEMBL10302375 | 0.83 | FFAR1 (0.38) | CNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2266941-A1 | TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | Chisso Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CNR2 2145/4885HTR2A 1823/4885HTR2C 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.